INNOGEN-B (02591) core product included in the "National Medical Insurance Drug List"

19:19 07/12/2025

Yinuo Medicine-B (02591) announced that the group's core product (ie. Ipragliflozin) has been successfully included in the latest version of China's National Reimbursement Drug List (2025 Edition) for the treatment of type 2 diabetes ("T2D") indications. The latest version of the National Reimbursement Drug List will officially take effect on January 1, 2026.

INNOGEN-B (02591) announces that the group's core product (i.e. exenatide alpha) has successfully been included in the latest version of China's National Drug Reimbursement List (2025 edition) for the treatment of type 2 diabetes ("T2D"). The latest version of the National Drug Reimbursement List will officially take effect on January 1, 2026.

Software crashed together? Roblox (RBLX.US): It has an ecological closed-loop, Genie can't break.

Industrial: Hong Kong stock market sentiment index has reached the bottom area.

"The 'Chinese Choice' for Global SiC Core Customers: Why TIANYU SEMI (02658)?"

Software crashed together? Roblox (RBLX.US): It has an ecological closed-loop, Genie can't break.

Industrial: Hong Kong stock market sentiment index has reached the bottom area.

"The 'Chinese Choice' for Global SiC Core Customers: Why TIANYU SEMI (02658)?"